Gland Pharma Q2 FY27 Results: Profit Rises 58% to ₹290.8 Crore as Revenue Grows 23%

10 November 2026
Curated by the team of Boldvoices

Gland Pharma Limited has delivered a strong year-on-year improvement in its September-quarter financial performance, with consolidated revenue, operating earnings and net profit all rising sharply. The Hyderabad-based injectable medicines manufacturer reported revenue from operations of ₹1,833.6 crore for Q2 FY 2026-27, up 23% from the corresponding quarter last year. Net profit increased 58% to ₹290.8 crore, while EBITDA rose 53% to ₹480.4 crore.

The results, approved by the board on 6 November 2026, were supported by growth in the company’s contract development and manufacturing organisation (CDMO) business and critical injectables portfolio. However, the quarter was not uniformly strong across markets: the United States and Europe grew, while India and some other international markets recorded declines.

Gland Pharma Q2 FY27: consolidated financial performance

The expansion in EBITDA margin from 21% to 26% indicates that operating earnings grew faster than revenue. The company’s reported adjusted EBITDA was ₹503 crore, up 50%. Adjusted EBITDA is a separate company-defined measure that adds employee stock-option compensation expenses and a one-off GST-related provision to EBITDA; the two figures should not be treated as identical.

Quarter-on-quarter picture: profit eased from Q1

The year-on-year growth rates are strong, but the sequential comparison provides a more balanced view. Revenue increased around 2% from Q1 FY27 to ₹1,833.6 crore, while EBITDA declined about 3% from ₹493 crore. Net profit fell approximately 8% from ₹317 crore to ₹290.8 crore.

This means the company’s performance improved substantially compared with the same quarter last year, but profitability moderated from the immediately preceding quarter. Investors following the business should therefore watch whether the stronger annual margins can be sustained as product launches, manufacturing volumes and regional demand evolve.

CDMO business grows 31%; critical injectables rise 18%

Gland Pharma’s two major business lines both recorded year-on-year growth in Q2 FY27:

CDMO growth was supported by recent product launches and higher volumes. The critical injectables business benefited from new launches and increased demand from existing customers. The company said that both businesses contributed to the quarter’s growth, with CDMO expanding faster than the overall company.

CDMO companies develop and manufacture products for other pharmaceutical businesses. This model can provide longer-term customer relationships and manufacturing opportunities, but it also requires regulatory compliance, reliable quality systems, technical capabilities and consistent delivery. Gland’s ability to deepen partnerships and convert its development pipeline into commercial manufacturing will be important to future growth.

United States leads regional performance

The United States remained Gland Pharma’s largest market, accounting for approximately 64% of Q2 FY27 revenue. US revenue reached about ₹1,179.5 crore, an increase of 42% year-on-year. The company attributed growth to recent product launches and higher volumes in existing products across CDMO and critical injectables.

Europe contributed around 20% of revenue. The region generated approximately ₹371 crore, up 30% year-on-year, supported by CDMO launches and volume expansion in existing products.

Performance was weaker in some other markets. Revenue from the rest of the world declined 21% to approximately ₹204.4 crore, with the company pointing to lower volumes linked to delayed tender business in the Middle East. Other core markets, including Canada, Australia and New Zealand, declined 18% to around ₹40 crore. India revenue fell 42% to approximately ₹38.7 crore, with lower volume uptake cited as the key factor.

The regional mix is an important part of the story. Strong US and European growth more than offset weaker contributions from India and other international markets. Continued dependence on the US also makes regulatory compliance, product approvals, competition and customer demand in that market particularly significant for the company.

New launches, regulatory filings and R&D pipeline

Gland Pharma reported several product-development milestones during the quarter:

• Four US launches: Sugammadex, Erythromycin, Fluorouracil and Atropine Sulfate were launched in the United States during Q2 FY27.
• ANDA activity: The company filed 11 Abbreviated New Drug Applications and received 10 approvals during the quarter.
• Cumulative US filings: Its total reached 399 ANDA filings, of which 350 had been approved and 49 were pending, according to the investor presentation.
• R&D investment: Research and development expenses were ₹107.7 crore, equivalent to around 6% of consolidated revenue, compared with ₹81.7 crore in Q2 FY26.
• Complex injectables: Six products from the in-house complex pipeline had been launched, with three more in line for approval.
• Ready-to-use infusion bags: The company had filed 24 products and received 18 approvals, with eight additional products under development.

Gland also said 15 products were in co-development partnerships, with commercialisation anticipated to begin in FY29. These programmes may support the longer-term pipeline, although their eventual contribution will depend on development progress, regulatory outcomes and commercial launches.

Manufacturing quality and regulatory compliance remain central

For an injectable medicines manufacturer, product quality and regulatory compliance are essential business requirements. Gland’s investor presentation said two of its facilities were audited by the US Food and Drug Administration. The VSEZ facility had zero observations, while the Dundigal inspection concluded in October 2026 with four procedural observations.

These details should be read precisely: the company described the Dundigal observations as procedural. The number and nature of inspection observations alone do not establish the wider regulatory status of every product or facility. Continued compliance, corrective actions where required and consistent manufacturing standards remain important for maintaining access to regulated markets.

First-half FY27 performance

For the six months ended 30 September 2026, consolidated revenue from operations increased 21% year-on-year to approximately ₹3,633.9 crore. EBITDA rose 43% to ₹973.4 crore, while net profit grew 52% to approximately ₹607.7 crore.

The first-half figures indicate that the Q2 improvement was part of a broader year-to-date expansion rather than an isolated quarterly movement. At the same time, the sequential moderation between Q1 and Q2 shows why investors should continue to assess quarterly trends, not just cumulative growth rates.

What to watch in the coming quarters

• US business momentum: Whether new launches and higher volumes continue to support the largest regional market.
• CDMO partnerships: Conversion of customer engagements, technology transfers and manufacturing contracts into sustained revenue.
• Critical injectables: Growth from new approvals and increased demand from existing customers.
• Regional recovery: Improvement in India, the Middle East and other markets where Q2 revenue declined.
• R&D productivity: Commercial progress from the company’s complex injectables and ready-to-use product pipeline.
• Margins and cash flow: Whether operating profitability and cash generation remain healthy as the business expands.

Bottom line

Gland Pharma’s Q2 FY27 results show strong year-on-year growth, with revenue up 23%, EBITDA up 53% and net profit up 58%. The CDMO business and US market were major growth contributors, while Europe also performed well. Yet the quarter-on-quarter decline in net profit and weakness in India and some other markets underline that the performance was not uniform. The next phase will depend on sustaining launches, deepening manufacturing partnerships, maintaining regulatory standards and converting its development pipeline into profitable growth.

This article is for general news and information purposes only. It is not investment advice or a recommendation to buy, sell or hold any security. Financial figures are based on Gland Pharma’s unaudited consolidated results and Q2 FY27 investor presentation.

Official company documents: Gland Pharma Q2 FY27 financial results and investor presentation.

#GlandPharma #GlandPharmaResults #Q2FY27 #PharmaceuticalIndustry #CDMO #Injectables #IndiaBusiness #BusinessAndEconomy #CorporateResults #BoldVoices